Drug Details

General Information of the Drug (ID: DR9295)
Name
Tegafur
Synonyms
tegafur; Ftorafur; 17902-23-7; Futraful; Fluorofur; Sinoflurol; Citofur; Florafur; Fental; Neberk; Coparogin; Franroze; Furafluor; Furflucil; Furofutran; Nitobanil; Exonal; Fulfeel; Lifril; Sunfral; Lamar; Riol; Tefsiel C; FT-207; 5-fluoro-1-(tetrahydrofuran-2-yl)pyrimidine-2,4(1H,3H)-dione; Phthorafur; 1-(2-Tetrahydrofuryl)-5-fluorouracil; 5-Fluoro-1-(tetrahydro-2-furyl)uracil; 2,4(1H,3H)-Pyrimidinedione, 5-fluoro-1-(tetrahydro-2-furanyl)-; MJF-12264; NSC-148958; N1-(2-tetrahydrofuryl)-5-fluorouracil; 1-(Tetrahydrofuran-2-yl)-5-fluorouracil; 5-Fluoro-1-(tetrahydrofuran-2-yl)uracil; URACIL, 5-FLUORO-1-(TETRAHYDRO-2-FURYL)-; 5-Fluoro-1-(tetrahydro-2-furanyl)-2,4-pyrimidinedione; Uracil, 1-(tetrahydrofuran-2-yl)-5-fluoro-; FT 207; MFCD00012351; 5-Fluoro-1-(tetrahydro-3-furyl)uracil; 1-(Tetrahydro-2-furanyl)-5-fluoro-2,4-pyrimidinedione; MLS000069497; 5-FLUORO-1-(TETRAHYDRO-2-FURFURYL)URACIL; CHEBI:32188; 1-(2-TETRAHYDROFORMYL)-5-FLUOROURACIL; C8H9FN2O3; 5-fluoro-1-tetrahydrofuran-2-yl-pyrimidine-2,4-dione; NCGC00159418-02; NCGC00159418-05; SMR000059106; Racemic Ftorafur; DSSTox_CID_1305; DSSTox_RID_76070; DSSTox_GSID_21305; Phthorafur [Czech]; Fluorafur; Tegafurum; Tegafurum [INN-Latin]; CAS-37076-68-9; CCRIS 2762; FT-207 (NSC 148958); FT207; EINECS 241-846-2; BRN 0525766; Franrose; N1-(2'-Tetrahydrofuryl)-5-fluorouracil; Sunfural; Fulaid; 1-(Tetrahydro-2-furanyl)-5-fluorouracil; N(sub 1)-(2-Tetrahydrofuryl)-5-fluorouracil; Tegafur [USAN:INN:BAN:JAN]; N(sub 1)-(2'-Furanidyl)-5-fluouracil [Czech]; Atillon (TN); Tegafur ,(S); N(sub 1)-(2'-Furanidyl)-5-fluouracil; TS-1 (Salt/Mix); Opera_ID_1726; UPCMLD-DP063; SCHEMBL4552; 5-fluoro-1-(oxolan-2-yl)pyrimidine-2,4-dione; 5-24-06-00285 (Beilstein Handbook Reference); MLS000759414; MLS001076521; MLS001424119; CHEMBL20883; Tegafur (JP17/USAN/INN); F-5-FU; UPCMLD-DP063:001; GTPL10513; DTXSID001009966; HMS1665I05; HMS2051B15; HMS2090K04; HMS2232E05; HMS3371H21; HMS3393B15; HMS3654P13; HMS3715D14; N1-(2'-Furanidyl)-5-fluouracil; 2,4(1H,3H)Pyrimidinedione, 5-fluoro-1-(tetrahydro-2-furanyl)-; 5-Fluoro-1-(tetrahydro-2-furanyl)-2,4(1H,3H)-pyrimidinedione; BCP22714; 5-fluoro-1-(tetrahydrofuran-2-yl); N1-(2'-Furanidyl)-5-fluorouracil; Tox21_111649; Tox21_301812; BBL027795; CCG-50110; STK528044; Tegafur, >=98% (HPLC), powder; 5-Fluoro-1-(2-tetrahydrofuryl)uracil; AKOS000121279; Tox21_111649_1; AC-2112; CCG-100959; CS-1128; DB09256; MCULE-1366455644; NC00209; 1-(tetrahydro-2-furyl)-5-fluorouracil; 2,4(1H,3H)-Pyrimidinedione, 5-fluoro-1-(tetrahydro-2-furanyl)-, didehydroderiv.; 5-fluoro-1-(2-tetrahydrofuranyl)uracil; N1 -(2-tetrahydrofuryl)-5-fluorouracil; NCGC00159418-04; NCGC00255222-01; 79107-97-4; 82294-77-7; AK468738; AS-13528; HY-17400; I580; FT-0653732; FT-0654170; FT-0674829; FT-0693965; C12673; D01244; J10344; W-5041; AB00572620-15; 902T237; Q413370; SR-01000639511; Q-201784; SR-01000639511-1; SR-01000639511-4; 5-fluoro-1-tetrahydro-furan-2-yl-1H-pyrimidine-2,4-dione; 5-Fluoro-1-tetrahydro-2-furanyl-2,4(1H,3H)-pyrimidinedione; 2, 4(1H,3H)-Pyrimidinedione, 5-fluoro-1-(tetrahydro-2-furanyl)-, (R)-
    Click to Show/Hide
Molecular Type
Small molecule
Disease Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved [1]
Structure
Click to Download Mol
2D MOL

3D MOL

ADMET Property
Absorption Tmax
The time to maximum plasma concentration (Tmax) is 1-2 h
Clearance
The drug present in the plasma can be removed from the body at the rate of 0.95 mL/min/kg
Elimination
About less 20% of total dose is excreted unchanged in the urine
Half-life
The concentration or amount of drug in body reduced by one-half in 11 hours
Metabolism
The drug is metabolized via the hepatic
Vd
Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 0.62 L/kg
    Click to Show/Hide
    Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product
Formula
C8H9FN2O3
PubChem CID
5386
Canonical SMILES
C1CC(OC1)N2C=C(C(=O)NC2=O)F
InChI
1S/C8H9FN2O3/c9-5-4-11(6-2-1-3-14-6)8(13)10-7(5)12/h4,6H,1-3H2,(H,10,12,13)
InChIKey
WFWLQNSHRPWKFK-UHFFFAOYSA-N
CAS Number
CAS 17902-23-7
ChEBI ID
CHEBI:32188
TTD Drug ID
D0F3SY
DrugBank ID
DB09256
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally
    α. A List of Natural Product(s) Able to Enhance the Efficacy of This Drug
          Cystine      Gallus gallus     Click to Show/Hide the Molecular Data of This NP
                 Achieving Therapeutic Synergy     Click to Show/Hide
                    Representative Experiment Reporting the Effect of This Combination [2]
                    Detail(s)  Combination Info  click to show the detail info of this combination
                    Experimental
                    Result(s)		 The chemotherapeutic action of tegafur (FT) against adenocarcinoma 755 in mice was markedly potentiated by oral administration of L-cysteine and L-cystine without increasing its toxicity.
References
Reference 1 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
Reference 2 Potentiation of the chemotherapeutic action of tegafur against solid adenocarcinoma 755 by combination with L-cystine. J Cancer Res Clin Oncol. 1986;111(3):187-90.
 Download Picture         KEGG Link